STOCK TITAN

PACIFIC SOFTWARE INC - PFSF STOCK NEWS

Welcome to our dedicated page for PACIFIC SOFTWARE news (Ticker: PFSF), a resource for investors and traders seeking the latest updates and insights on PACIFIC SOFTWARE stock.

Pacific Software Inc. (PFSF) is a pioneering company in the skincare industry, known for its innovative peptide inhibitors of insulin-degrading enzyme (IDE) developed in collaboration with the University of California. These IDE inhibitors, marketed as Dermatrix™, have significant implications for wound healing and cosmetics by boosting collagen production through a novel mechanism. With a commitment to cutting-edge research and transformative products, Pacific is dedicated to advancing skincare solutions for societal benefit.

Rhea-AI Summary

Pacific Software Inc. (OTC:PFSF) has appointed Professor Dr. Robert Schiestl Ph.D. as its Chief Science Advisor (CSA). Dr. Schiestl, a distinguished scientist with over 200 peer-reviewed publications and 16 patents, brings extensive expertise in molecular toxicology, cancer prevention, and genomics. His research focuses on genetic stability and strategies to prevent genetic diseases and cancer, aligning with Pacific Software's mission to develop innovative skincare products and science-based dietary supplements.

Dr. Schiestl's background includes positions at Harvard School of Public Health and UCLA, where he is currently Professor Emeritus. His work on oxidative stress and its health impacts is particularly relevant to Pacific Software's objectives. CEO Harrysen Mittler expressed enthusiasm about Dr. Schiestl's potential contributions to advancing the company's cosmeceutical technology and supplement offerings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Pacific Software announced the acquisition of a dietary supplement designed to support brain health and memory, marketed as SuppleMEM AD™ and A.L.Z. Defense™.

The formula, tested by leading Alzheimer's researchers, has been sold for over 8 years. The company is obtaining quotes to manufacture this product in the USA and Mexico, targeting distribution in the third quarter of 2024.

This acquisition aligns with Pacific's strategy to diversify into health and skin care products. The core formula, a blend of natural ingredients, has shown positive results in NIH-funded studies at UC Irvine and the University of Kentucky.

The company expects revenue from retail and wholesale channels. Dr. Leissring resigned as president on June 18, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Pacific Software announced its acquisition of a science-based dietary supplement focused on brain health and memory function, sold under the brand names SuppleMEM AD™ and A.L.Z. Defense™. This acquisition marks Pacific's expansion beyond its previous focus on skin care and wound healing. CEO Harrysen Mittler stated the product has been profitable for over 8 years, and studies funded by the NIH at the University of California, Irvine, and the University of Kentucky have validated its effectiveness. Pacific's President, Dr. Malcolm Leissring, emphasized that proceeds will support the AD Foundation's Alzheimer’s prevention initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Pacific Software has secured an exclusive licensing agreement with the University of California to develop, manufacture, and commercialize innovative peptide inhibitors of insulin-degrading enzyme (IDE) for skincare and wound healing applications.

The technology, developed with over $6 million in research funding, will be spearheaded by Dr. Malcolm A. Leissring, who will become the Chief Science Officer of Pacific.

The IDE inhibitors, marketed as Dermatrix™, have shown significant capabilities in boosting collagen production, making them revolutionary for both wound healing and cosmetics. The agreement, effective as of March 5, 2024, also makes UC Regents an equity partner in Pacific.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Pacific Software Inc. (PFSF) announced the acquisition of certain assets from Dreamaderm Inc., including a patented cosmeceutical technology called Dermatrix. Dermatrix boosts collagen production by preserving insulin in the skin, offering a wide range of dermatological applications. The technology was developed by Dr. Malcolm A. Leissring and has the potential to revolutionize the cosmetics and skin care industry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
-
Rhea-AI Summary

Pacific Software, Inc. (OTCPINK:PFSF) has issued a letter to shareholders highlighting its achievements and future plans. In 2021, the company undertook significant restructuring and made strides in development with multiple joint ventures and acquisitions. Key successes include launching partnerships with Lincoln Clark and Raffaele Gallo, along with a 51% acquisition of a World of Beer tavern. Looking ahead, the company anticipates several new restaurant openings and a rebranding to align with its growth strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Pacific Software, Inc. (OTC PINK:PFSF) announced a debt restructuring of approximately $3,000,000 to enhance its capital structure ahead of its growth initiatives for 2022. The restructuring moves legacy notes from a fixed percentage to a fixed price conversion rate, eliminating liability premiums and interest expenses. This adjustment is expected to simplify accounting and improve financial transparency. The company aims to launch several new restaurant locations and brands soon, indicating a robust growth strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
none
-
Rhea-AI Summary

Pacific Software, Inc. (OTCPINK:PFSF) is repositioning to enter the fast casual restaurant market, projected to grow from $125.6 billion in 2019 to $209.1 billion by 2027, at a CAGR of 10.6%.

To spearhead this transition, the company has appointed Isaac Onn as CEO and Michael Finkelstein as COO, both with extensive industry experience. Their strategy includes acquiring restaurant chains affected by the Covid-19 pandemic, aiming to build a diverse cash flow portfolio. The company will also undergo a name change and is launching a new website soon.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of PACIFIC SOFTWARE (PFSF)?

The current stock price of PACIFIC SOFTWARE (PFSF) is $0.0126 as of December 12, 2024.

What is the market cap of PACIFIC SOFTWARE (PFSF)?

The market cap of PACIFIC SOFTWARE (PFSF) is approximately 423.6K.

What is Pacific Software Inc. known for?

Pacific Software Inc. is known for its groundbreaking skincare products, particularly its peptide inhibitors of insulin-degrading enzyme (IDE) developed in partnership with the University of California.

What are IDE inhibitors and how do they work?

IDE inhibitors are molecules that block the enzyme insulin-degrading enzyme (IDE), preventing insulin breakdown and boosting collagen production in skin cells. This mechanism has applications in wound healing and cosmetics.

What is the significance of the licensing agreement with the University of California?

The licensing agreement grants Pacific exclusive rights to develop, manufacture, and commercialize IDE inhibitors developed at the University of California, Irvine, highlighting Pacific's dedication to advancing skincare solutions.

Who is Dr. Malcolm A. Leissring and what role does he play in Pacific Software Inc.?

Dr. Malcolm A. Leissring is a pioneer in pharmacology and Chief Science Officer of Pacific Software Inc. His research on IDE inhibitors has led to the development of transformative skincare products for wound healing and cosmetics.

What is the product marketed as Dermatrix™ and how does it work?

Dermatrix™ is the principal IDE inhibitor licensed by Pacific, designed to stimulate collagen production in skin cells. By blocking IDE, Dermatrix™ boosts insulin levels, promoting collagen mRNA and protein production for enhanced wound healing and cosmetics.

What is Pacific's mission and commitment in the skincare industry?

Pacific is committed to leveraging cutting-edge research for societal benefit by developing advanced skincare solutions. The company's dedication to transforming research into practical applications underscores its commitment to innovation and quality in the skincare sector.

What are the implications of IDE inhibitors for the cosmetics sector?

IDE inhibitors like Dermatrix™ have significant implications for the cosmetics sector, particularly in enhancing collagen production during cosmetic treatments. By maximizing collagen synthesis, IDE inhibitors offer game-changing technology for various skincare procedures.

How does the exclusive license with the University of California benefit Pacific Software Inc.?

The exclusive license enables Pacific to utilize patented IDE inhibitors for developing advanced skincare solutions, reinforcing the company's position as a leader in skincare innovation. The collaboration with academia signifies a crucial step towards commercializing vital skincare innovations.

Who is Stephen Israel and what role does he play in Pacific Software Inc.?

Stephen Israel is the Chief Operating Officer of Pacific Software Inc. His role involves working closely with the University of California to bring research innovations to real-world applications, ensuring that Pacific's suite of products maximizes benefits for customers and patients globally.

What are the future prospects for Pacific Software Inc. in the skincare industry?

Pacific Software Inc. aims to continue developing advanced skincare solutions by leveraging cutting-edge research and transformative products. The company's focus on innovation and quality underscores its commitment to driving positive impact in the skincare sector.

PACIFIC SOFTWARE INC

OTC:PFSF

PFSF Rankings

PFSF Stock Data

423.64k
19.19M
Restaurants
Consumer Cyclical
Link
United States of America
Toronto